What do systematic reviews say?

CI: Confidence interval · adults with PPPD

Improvement in vertigo · adults with PPPD

Change in vertigo · adults with PPPD

Potency/bioactivity parameters of human insulin · healthy physicians

Diabetic ketoacidosis · healthy physicians

Hypoglycaemic episodes · healthy physicians

Adverse events · healthy physicians

Health‐related quality of life · healthy physicians

HbA1c · healthy physicians

Viral clearance at 14 days · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

Participants with new need for invasive mechanical ventilation or death · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Participants discharged alive. Participants should be discharged without clinical deterioration or death · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Quality of life up to 28 days and longest · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

SAEs during the study period · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Any grade TEAE · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Any grade TRAE · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Discontinuation of study drug due to adverse events · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Viral clearance · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Admission to ICU or death · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

All initial symptoms resolved at 28 days, and up to the longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease